Earnings Preview: What To Expect From Teva Pharmaceutical On Monday
Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire
Articles with Teva Pharmaceuticals, Inc. | page 2
DAUNORUBICIN Hydrochloride Injection
Patent Docs: Eli Lilly & Co. v. Teva Parenteral Medicines, Inc. (Fed. Cir. 2012)
UPDATE 2-Teva halts output at U.S. drug plant after FDA flags concerns
Teva Parenteral Medicines Initiates Voluntary Nationwide Recall of Select Lots of Adrucil® (fluorouracil injection, USP) 5 g/100 mL (50 mg/mL) Due to Particulate Matter | Business Wire
The Medicines Company settles patent infringement lawsuits with Teva | NASDAQ:MDCO
Teva charts 300-plus layoffs at troubled California injectables plant
Teva halts output at U.S. drug plant after FDA flags concerns | Reuters